CDKN2A and neoplasm: Early genome‐wide association studies on familial melanoma identified that cyclin‐dependent kinase inhibitor 2A (CDKN2A) was a melanoma risk loci, which encodes two tumor suppressors, P14ARFand P16INK4a.